Abstract
The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Current Pharmaceutical Biotechnology
Title: Rodent Models of Persistent Pain in Drug Discovery and Development
Volume: 12 Issue: 10
Author(s): William A. Eckert
Affiliation:
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Abstract: The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Export Options
About this article
Cite this article as:
A. Eckert William, Rodent Models of Persistent Pain in Drug Discovery and Development, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357456
DOI https://dx.doi.org/10.2174/138920111798357456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Endothelin-1 Impairs Retrograde Axonal Transport and Leads to Axonal Injury in Rat Optic Nerve
Current Neurovascular Research Antihyperglycemic Effects of Formulation of Spray Dried Fruit Juice of Emblica officinalis in Streptozotocin Induced Diabetic Rats.
Current Nutrition & Food Science Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology Development of Mobile Tracking System for Diabetes and Recent Patents on Diabetes Mellitus
Recent Patents on Engineering Diabetes, Diabetic Complications, and Phosphate Toxicity: A Scoping Review
Current Diabetes Reviews An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) CYP Inhibition-Mediated Drug-Drug Interactions
Current Enzyme Inhibition Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Chemistry and Biology of Gluten Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Aldose Reductase: A Novel Target for Cardioprotective Interventions
Current Drug Targets Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design The Ayurvedic Bhasma: The Ancient Science of Nanomedicine
Recent Patents on Nanomedicine Pathophysiology of Erectile Dysfunction
Current Drug Targets Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine